Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

GLPG 5101

Next Previous
X
Search
Drug Profile

GLPG 5101

Alternative Names: 19-CP-02; GLPG-5101

Latest Information Update: 26 Aug 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CellPoint Bio
  • Developer CellPoint Bio; Galapagos NV
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Non-Hodgkin's lymphoma
  • Phase I Systemic lupus erythematosus

Most Recent Events

  • 23 Aug 2024 US FDA approves an IND application for phase I/II ATALANTA-1 trial of GLPG 5101 in Non-Hodgkin's lymphoma (Second-line therapy or greater)
  • 01 Aug 2024 Galapagos files an IND application with the US FDA in USA for phase I/II ATALANTA-1 trial of GLPG 5101 in Non-Hodgkin's lymphoma
  • 17 Jun 2024 Additional efficacy and adverse events data from the phase I/II ATALANTA-1 trial in Non-Hodgkin lymphoma released by Galapagos

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top